ホーム › 頭頸部扁平上皮癌 › ペンシルベニア › Pittsburgh
Pittsburgh、PAにおける頭頸部扁平上皮癌の臨床試験
Pittsburghとその周辺地域（約30マイル以内）の拠点で、頭頸部扁平上皮癌に関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
被験者募集中第3相
- Allegheny General Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- 他7件
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
被験者募集中第2/3相
- Site #0103, Pittsburgh
- Site #0123, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #32, Pittsburgh
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
被験者募集中第3相
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- 他4件
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
被験者募集中第1相
- Research Site, Pittsburgh
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
被験者募集中第2相
- UPMC Hillman Cancer Center, Pittsburgh
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
被験者募集中第2相
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- 他9件
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site, Pittsburgh
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
被験者募集中第2/3相
- UPMC-Magee Womens Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
被験者募集中第2相
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- 他5件
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
被験者募集中第2相
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- GSK Investigational Site, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
被験者募集中第2相
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
被験者募集中第1相
- UPMC- Hillman Cancer Center, Pittsburgh
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
被験者募集中第2相
- UPMC, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- University of Pittsburgh Medical Center, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
被験者募集中第1相
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
被験者募集中第1/2相
- University of Pittsburgh, Pittsburgh
他の都市における頭頸部扁平上皮癌の試験
- Houston, TX47件の研究
- Los Angeles, CA42件の研究
- Boston, MA40件の研究
- New York City, NY39件の研究
- Nashville, TN39件の研究
- St. Louis, MO28件の研究
- Arlington, VA26件の研究
- Philadelphia, PA26件の研究
- Chicago, IL26件の研究
- Atlanta, GA24件の研究
- San Antonio, TX22件の研究
- New Haven, CT22件の研究
Pittsburghにおける他の研究
- 非小細胞肺癌48件の研究
- がん（全種類）41件の研究
- 乳がん39件の研究
- 大腸癌32件の研究
- 転移性癌31件の研究
- 悪性黒色腫31件の研究
- 卵巣がん30件の研究
- 子宮内膜がん23件の研究
- 前立腺がん23件の研究
- 肺がん23件の研究
- 脳卒中22件の研究
- うつ病22件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。